Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)

计划入组 432 人 · 首次发布于 2021 年 8 月 31 日

Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

计划入组 304 人 · 首次发布于 2019 年 10 月 16 日

Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis

计划入组 22 人 · 首次发布于 2026 年 1 月 14 日

Inonotus obliquus fruiting body

Psoriasis(Antolrx)

Psoriasis therapeutic

BODY AND SOUL HEALTH PRODUCTS PTY LTD

New Zealand

Bath & Body Works

United States

PSORIASIS TREATMENT CENTER OF SOUTH FLORIDA

United States

FDA Accepts Roflumilast Foam sNDA for Scalp and Body Psoriasis Treatment

FDA Anticipated to Decide on Dupixent, Pz-cel, and Roflumilast Foam for Dermatologic Conditions by Mid-2025

Dermatology News Roundup: Bimzelx Expansion, Zoryve sNDA, and HS Insights